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Abstract
Background
Transcatheter aortic valve implantation (TAVI) is a minimally invasive procedure used to
treat degenerative heart valve disease. The implantation requires a highly specific and inter-
disciplinary management approach. Currently, TAVI is performed with the patient under
local or general anaesthesia.
Methods
This study was a retrospective analysis of all TAVI procedures performed at the University
Hospital of Regensburg between January 2009 and July 2015. All pre-, intra and postopera-
tive data focusing on perioperative complications were recorded.
Results
A total of 853 transfemoral- and transapical-TAVI patients were included in the study. All
patients underwent general anaesthesia. The ASA classifications were primarily 3–4. The
average logistic EuroScores for the transfemoral- and transapical-TAVI patients were 18 ±
12% and 21 ± 15% (p = 0.002), respectively. The anaesthesia coverage time was 170 ± 49
min., including 37 ± 12 minutes for anaesthetic management. Overall, 458 complications
were recorded; with pneumonia, acute renal failure, indication for a permanent pacemaker
and non-extubation in the operating theatre the most frequently recorded complications.
Conclusion
In the present study, we showed that our patients’ outcomes are comparable to those
reported in the available literature. Compared to TF, TA patients show an overall worse
physical condition as well as a higher perioperative morbidity and mortality. Consequently
TA patients need additional care and should only be operated in appropriately experienced
medical centres.
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Introduction
The most common form of heart valve disease in western countries is aortic valve stenosis. [1]
Its prevalence among patients older than 65 years of age is 2% to 7%. [2] Etiologically, the
most common cause is valve calcification. [1] Surgical aortic valve replacement is currently the
gold standard for treating aortic valve stenosis in low- or intermediate-risk patients. [3]
Transcatheter aortic valve implantation (TAVI) is a minimally invasive surgical procedure
that was initially developed as an alternative treatment for patients with a high level of periop-
erative risk, and it has since established itself in this field. [4] TAVI involves the implantation
of a prosthetic valve mounted on a stent and introduced with a catheter through transfemoral
(TF), transapical (TA), transaxillary/subclavian or direct transaortic access. [5] Usually, the TF
approach is preferred, because thoracotomy and penetration of the myocardium are not
needed. The TA approach is common, if severe atherosclerotic disease does not allow retro-
grade insertion of the catheter. [6] The first TAVI was performed by Cribier et al. in 2002. [7]
In 2010, 4,859 TAVIs were performed in Germany. In 2013, minimally invasive procedures
(10,441) exceeded open surgical (9,899) procedures for the first time. [8] Because the number
of surgical interventions remained virtually constant during this time, TAVI was used for
patients for whom only a conservative approach had been previously available. While the first
TAVI was performed under monitored anaesthetic care (MAC), general anaesthesia (GA) was
typically utilized in the early years. [7] In recent years, TAVIs, through TF access, have often
been performed under local anaesthesia and MAC in Germany. [8] For anaesthesiologists,
TAVI is challenging for many reasons. First, many patients have a serious pre-existing condi-
tion and these are therefore high-risk patients. [5] Second, these patients are exposed to
marked hemodynamic fluctuations during the TAVI procedure, for example, due to functional
heart arrest through rapid pacing. To mitigate the risk of cardiopulmonary decompensation, a
highly specific and interdisciplinary management approach is required, possibly including the
deployment of extracorporeal membrane oxygenation (ECMO). [9]
For the present article, all TAVI interventions performed at our hospital using TF and TA
access were evaluated retrospectively. The goal was to collect key information about the differ-
ent types of operations, typical complications and procedural parameters in the context of
benchmarking and to compare these results with the current literature.
Materials and methods
General information, data collection and definitions
After obtaining the consent of the University of Regensburg’s Ethics Commission, all TA- and
TF-TAVI patients who had been treated at the University Hospital Regensburg during the
period of interest, namely, January 2009 to July 2015, were retrospectively included. TAVIs
using other types of access were excluded. The consulted sources included anaesthesia records
(Medlinq1, Hamburg, Germany), data from the patient data management system (PDMS,
Metavision1, Tel Aviv, Israel) and intensive care unit (ICU), as well as records, medical
reports and quality management (QM) data from the hospital information system (SAP1,
Walldorf, Germany). The period of observation ended with the discharge of the patient from
the hospital. The data were collected in a standardized and anonymized format.
Preoperative data. Preoperative data from the anaesthesia records and medical reports
included demographic data, such as age, sex, height, weight, American Society of Anesthesiolo-
gists (ASA) class, logistic EuroScore (European System for Cardiac Operative Risk Evaluation),
New York Heart Association (NYHA) class, long-term medication, haemoglobin level and left-
ventricular ejection fraction (EF). The patients’ previous medical history was examined for
TAVI and anaesthesia
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conditions such as chronic kidney disease (CKD), cerebrovascular events (CVEs), including
stroke and transient ischemic attacks (TIAs), myocardial infarction (MI), chronic obstructive
pulmonary disease (COPD), diabetes mellitus (DM), and pre-existing cardiac arrhythmias.
Intraoperative data. Key elements of intraoperative data included the selected access
type, date of the operation, prosthesis type, anaesthetic procedure, cardiopulmonary resuscita-
tion (CPR), use of ECMO, transfusion of erythrocyte concentrates and extubation rate, as well
as the induction, procedure, and emergence durations. The study periods were defined as fol-
low: “induction” from the start of the anaesthetic treatment until entering of the hybrid operat-
ing theatre, “procedure time” from the skin incision to the closure of the incision, and
“emergence” from the closure of the incision to the end of the anaesthetic treatment. The
“anaesthesia coverage time” was defined as the time from the start to the end of the anaesthetic
treatment. Surgical complication data were also collected, including pericardial effusion, annu-
lar rupture, ventricular perforation, vascular complication of the access vessels, bleeding, valve
dislocation, and balloon rupture. CVEs, MIs and procedure changes were also documented.
Postoperative data. Postoperative data included the patient’s stay in the ICU (ICU rec-
ords, QM data), IMC (intermediate care, IMC records, QM data), and stay in the general ward
(medical reports, QM data). Such data included the ventilation duration, respective length of
stay, transfusion of erythrocyte concentrates, and implantation of a permanent pacemaker
(PM), as well as complications, such CVE, MI, acute kidney injury (AKI), pneumonia and sep-
sis. The mobilization time describes the period from admission to the ICU to the first mobili-
zation out of bed. The mortality data reference in-hospital mortalities. Mortality reasons are
divided into cardiac, AKI, CVE, bleeding and infections. Cardiac reasons include MI, cardiac
arrest, ventricular fibrillation and heart failure. Bleeding includes retroperitoneal bleeding,
ventricular perforation, haematothorax and gastrointestinal bleeding.
Description of the procedure
All patients were admitted and evaluated at least one day before the operation. TAVIs were
performed by the cardiac team (cardiac surgeon, cardiologist, and cardiac anaesthetist) in a
hybrid operating theatre. All licensed valve types were deployed. Anaesthesia was induced
with etomidate (Etomidat-Lipuro1, B. Braun Melsungen AG, Melsungen, Germany), remi-
fentanil (Ultiva1, GlaxoSmithKline GmbH & Co. KG, Munich, Germany) and rocuronium
(Rocuronium Inresa1, Inresa Arzneimittel GmbH, Freiburg, Germany) and maintained with
sevoflurane (Sevorane1, AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany). Nor-
epinephrine (Arterenol1, Sanofi-Aventis-Deutschland GmbH, Frankfurt a. Main, Germany)
was continuously administered through intravenous infusion at the discretion of the attending
to achieve an adequate circulatory support. A prophylactic antibiotic (1.5 g Cefuroxim
Hikma1, Hikma Pharma GmbH, Gra¨felfing, Germany) was administered to each patient. In
the operating theatre, the patient was connected to a defibrillator, and a TEE probe was intro-
duced. After preparing the access points and anticoagulation with heparin (Ratiopharm
GmbH, Ulm, Germany; mean given dose: 5293 ± 2643 IU), the native valve was opened under
rapid ventricular pacing (RVP), and the prosthesis was implanted. The position and function
of the prosthesis was verified with TEE. Extubation of the patient was the goal at the end of
each procedure. After surgery, patients were monitored for at least 12 hours in the ICU or
IMC. Following this period, patient care continued either in the ICU or in the general ward.
Data processing
The data were analysed with SPSS (IBM Corp., Armonk, USA, version 23) by applying Pear-
son’s chi-squared test, t-tests, Mann-Whitney-U-Test and logistic regression. A p-value
TAVI and anaesthesia
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of< 0.05 was considered to be statistically significant. All data in the text, tables and figures
are specified as a percent (%) or otherwise described in detail.
Results
During the time period investigated, 853 TF- and TA-TAVI patients were included in the
study. Data for 100% of these patients were analysed. TF access was selected for 506 patients
(59%), with TA chosen for 347 patients (41%). The demographic data and pre-existing condi-
tions are shown in Table 1. The TA patients’ average logistic EuroScore (TA: 21 ± 15% vs. TF:
18 ± 12%; p = 0.002) and their ASA-class (p = 0.033) were significantly higher than of the TF
patients’. The elective use of ECMO was similarly frequent in both groups (TF: n = 24 (5%),
TA: n = 15 (4%); p = 0.868).
Table 1. Demographic data.
all TF: n = 506 [59] TA: n = 347 [41] p
Age (years) 79 ± 6 79 ± 6 79 ± 6 0.238
Gender (female) 448 [53] 278 [55] 170 [49] 0.094
BMI (kg/m2) 27 ± 5 27 ± 5 27 ± 5 0.496
ASA Classification 3 3 3 0.033
1 0 0 0
2 7 [1] 3 [1] 4 [1]
3 574 [67] 357 [71] 217 [63]
4 264 [31] 141 [28] 123 [36]
5 3 [0] 2 [0] 1 [0]
Not specified 5 [1] 3 [1] 2 [1]
NYHA Classification 3 3 3 0.394
1 32 [4] 21 [4] 11 [3]
2 211 [25] 134 [27] 77 [22]
3 404 [47] 244 [48] 160 [46]
4 103 [12] 62 [12] 41 [12]
Not specified 103 [12] 45 [9] 58 [17]
Logistic EuroScore (%) 19 ± 14 18 ± 12 21 ± 15 0.002
EF (%) 54 ± 13 54 ± 13 53 ± 13 0.185
Normal (55%) 507 [59] 311 [62] 196 [57]
Slightly reduced (45–54%) 142 [17] 86 [17] 56 [16]
Moderately reduced (30–44%) 121 [14] 67 [13] 54 [16]
Severely reduced (<30%) 54 [6] 29 [6] 25 [7]
Not specified 29 [3] 13 [3] 16 [5]
History of CVE 138 [16] 81 [16] 57 [16] 0.925
History of myocardial infarction 65 [8] 34 [7] 31 [9] 0.239
Pacemaker pre-existing 105 [12] 72 [14] 33 [10] 0.044
DM 305 [36] 173 [34] 132 [38] 0.275
COPD 114 [13] 65 [13] 49 [14] 0.609
CRF 309 [36] 175 [35] 134 [39] 0.246
TF: transfemoral; TA: transapical; BMI: Body Mass Index; ASA: American Society of Anesthesiologists; NYHA: New York Heart Association; EF: Ejection fraction;
CVE: cerebrovascular events; DM: Diabetes mellitus; CRF: chronic renal failure
All data are presented as the mean ± standard deviation, median or number [%].
p < 0.05.
https://doi.org/10.1371/journal.pone.0193558.t001
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Overall, TA patients had significantly more complications per patient than TF patients (0.7
vs. 0.4; p = 0.001). Subsequently, the complications are addressed in detail. All complications
are summarized in Table 2.
Vascular complications
Vascular complications (e.g., bleeding, hematoma, dissection) arising from the intervention
were observed in 35 patients (4%). Such complications were significantly more frequent for
the TF patients than for the TA patients (6% vs. 2%; p = 0.013).
CVEs
A postoperative CVE occurred in 20 patients (2%). There was no significant difference in the
frequency of CVEs between the TF and TA patients (2% vs. 3%; p = 0.187).
MIs
Seven patients (1%), five TF patients and two TA patients experienced an MI during the
study period. Two TF patients and one TA patient had an MI during surgery. CPR was
applied on two occasions–once before RVP and once during RVP. In the third patient, ST-
segment elevation occurred after release of the prosthetic valve, without any serious haemo-
dynamic impairment. The vessel occlusions were each confirmed by coronary angiography.
The remaining four MIs occurred postoperatively. Three of these MIs expressed themselves
as an increase in cardiac enzymes on the same day as surgery or the day after, with one MI
being preceded by severe bleeding. In the case of the fourth patient, haemodynamic instabil-
ity occurred after a few days, with echocardiography revealing a dislocation of the prosthesis
leading to coronary occlusion. The incidence of MIs in patients with surgical complications
was significantly higher than in patients without surgical complications (3.7% vs. 0.5%;
p = 0.022).
Table 2. Complications.
Total TF (n = 506) TA (n = 347) p
All (n) 458 226 232
Mean per patient 0.5 0.4 0.7 0.001
Conversion rate to SAVR 9 [1] 4 [1] 5 [1] 0.498
Vascular complications 35 [4] 28 [6] 7[2] 0.013
CVE 20 [2] 9 [2] 11 [3] 0.249
MI 7 [1] 5 [1] 2 [1] 0.707
AKI 89 [10] 27 [5] 62 [18] <0.001
Pneumonia 62 [7] 29 [6] 33 [10] 0.044
Sepsis 17 [3] 5 [1] 12 [4] 0.022
Permanent PM 106 [12] 59 [12] 47 [14] 0.46
In-hospital Mortality 50 [6] 19 [4] 31 [9] 0.003
ECMO emergency 22 [3] 16 [3] 6 [2] 0.272
CPR 41 [5] 25 [5] 16 [5] 0.872
CVE: cerebrovascular events; MI: Myocardial infarction; AKI: acute kidney injury; PM: permanent pacemaker. All data are presented as number [%].
p < 0.05.
https://doi.org/10.1371/journal.pone.0193558.t002
TAVI and anaesthesia
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AKIs
An AKI occurred in a total of 89 patients (10%). The occurrence was significantly higher in the
TA patients than in the TF patients (TA: n = 62 (18%) vs. TF: n = 27 (5%); p< 0.001). Patients
who suffered an AKI had a significantly higher average EuroScore (27% vs. 18%; p< 0.001)
and a significantly lower average initial haemoglobin level (11.7 g/dl vs. 12.4 g/dl; p = 0.004).
In addition, they received 1.2 ± 2.9 erythrocyte concentrates on average during their hospital
stay, whereas patients without AKI received 0.4 ± 1.6 erythrocyte concentrates on average
(p = 0.007). Overall, 100 (12%) patients received erythrocyte concentrates.
Pneumonia
A total of 62 patients (7%) developed postoperative pneumonia. Patients with pneumonia
had a significantly longer stay at ICU (122 h vs. 38 h; p< 0.001) and in hospital (19 d vs. 10 d;
p<0.001). With each day that the patients spent in the hospital, the risk of contracting pneu-
monia increased by 6% (p< 0.001). With each hour that the patients spent in the ICU, the risk
of contracting pneumonia increased by 1% (p< 0.001). TA patients had a significantly higher
rate of pneumonia than TF patients (10% vs. 6%; p = 0.044). Patients who could not be extu-
bated in the operating theatre had a significantly higher rate of pneumonia than those who
were extubated immediately (15% vs. 6%; p = 0.004) and patients who had a ventilation > 48 h
had a significantly higher risk of contracting pneumonia than those who had a ventilation <
48 h (46% vs. 7%; p = 0.001). Non-extubation was mostly due to interventional complications
or side-effects. Overall, 10% of TF patients and 14% of TA patients could not be extubated in
the operating theatre (p = 0.083).
Permanent pacemaker
A total of 59 TF patients (12%) and 47 TA patients (14%; combined total 106 = 12%) required
postoperative fitting of a permanent PM. 72 TF Patients (14%) and 33 TA Patients (10%)
already had a PM before TAVI (p = 0.044). The need for postoperative implantation of a PM
was significantly higher in the patients with first-degree atrioventricular block (AV block),
incomplete left bundle branch block (LBBB) or right bundle branch block (RBBB). 21% of
patients with first-degree AV block and 12% of patients without first-degree AV block needed
a permanent PM (p = 0.029). 37% of patients with incomplete LBBB and 12% of patients
without incomplete LBBB needed a PM (p< 0.001). 28% of patients with RBBB and 12% of
patients without RBBB needed a PM (p = 0.001). Six patients had preoperative second-degree
AV block. Three of these patients had already had a PM fitted, and a further patient required
a permanent PM after the TAVI. The need for a permanent PM was also significantly higher
following implantation of a Medtronic CoreValve (CoreValve Revalving System, Medtronic,
Minneapolis, USA) (n = 28 (21%) vs. n = 63 (10%); p = 0.001). Apart from Medtronic Core-
Valve (n = 134 (16%)), we used Edwards SAPIEN (Edwards Lifesciences Corporation, Irvine,
USA) (n = 420 (49%)) and Symetis Valves (Boston Scientific Corporation, Marlborough, USA)
(n = 219 (26%)). In the rest of the cases (n = 80), the valve type could not be gathered from our
sources.
Conversion rate
Four TF patients (0.8%) and five TA patients (1.4%) were switched to an open surgical proce-
dure. The reasons for open surgery in the four TF patients were an embolization of the pros-
thesis into the ascending aorta, a perforation of the ventricle, and implantation problems due
to calcification of the aortic root. The fourth case could not be determined retrospectively. The
TAVI and anaesthesia
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reasons for open surgery in TA patients were severe regurgitation of the prosthesis in two
cases, a highly fragile myocardium in one patient, and a dislocation of the prosthesis in two
cases.
Mortality
The overall hospital mortality rate in our study was 6% (50 patients). There were 19 deaths
among the TF patients and 31 deaths among the TA patients (n = 19 (4%) vs. n = 31 (9%);
p = 0.002). The causes of death divided into TF and TA are shown in Fig 1. TF patients died
significantly more often by bleedings (n = 9 (47%) vs. n = 4 (13%); p = 0.018). CVEs were also
a more frequent death cause in TF patients, but without reaching statistical significance (n = 3
(16%) vs. n = 2 (7%); p = 0.355). TA patients died more often due to cardiac reasons (including
MI, acute heart failure and cardiac arrest) or infections than TF patients, but also without
reaching statistical significance.
Time specifications
The average anaesthesia coverage time for TA and TF was 174 ± 49 min. The mean anaesthesia
coverage time for TA access (180 ± 50 min) was significantly longer than that for TF access
(170 ± 48 min; p = 0.007). However, no difference was observed between TA and TF in terms
of the induction time (average: 37 ± 12 min), the procedure time (average: 87 ± 44 min) or the
emergence time (average: 7 ± 7 min). Significant differences between TF and TA were
observed concerning the length of stay at ICU (TF: 35 ± 52 h, TA: 57 ± 84 h; p< 0.001), IMC
(TF: 17 ± 51 h, TA: 60 ± 92 h; p< 0.001) and in hospital (TF: 10 ± 7 d, TA: 14 ± 11 d,
p< 0.001) and the time to mobilization (TF: 20 ± 18 h, TA: 34 ± 37 h; p< 0.001) (Table 3).
Discussion
This retrospective study enrolled data of 853 TAVI patients. TA access was associated with a
higher ASA-status, EuroScore and complication rate. AKI, pneumonia sepsis and mortality
were more often documented in TA group than TF group. In contrast, vascular complications
occurred more frequently in the TF group. Length of ICU, IMC and total hospital stay was
prolonged in the TA group.
The preoperative assessment revealed a higher ASA status and EuroScore for TA patients
than for TF patients. A higher ASA status corresponds to a higher incidence of perioperative
morbidity and mortality. [10] The EuroScore is the most widely used risk index for open car-
diac surgery, and it may be seen as an indicator for the TA patients to have a higher probability
Fig 1. Causes of death (in-hospital) with TF (transfemoral) and TA (transapical) access. All data are presented as
percentage. P-values were calculated from raw data: Cardiac (MI, acute heart failure and cardiac arrest): p = 0.148;
Acute kidney injury (AKI): p = 1; cerebrovascular events (CVE): p = 0.355; bleeding: p = 0.018; infection: p = 0.134.
https://doi.org/10.1371/journal.pone.0193558.g001
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to die due to the surgery. Although, this tool is primarily validated for open heart surgery, at
this moment it is also accepted to evaluate the TAVI risk. [11] Taken together, the anaesthesio-
logic, as well as the operative risk for TA patients was higher than for TF patients. The
increased length of stay on ICU, on IMC or in hospital may be attributed to this increased
assessed risk by itself. However, in the TA group more complications were documented,
which might even influence the length of the hospital stay. It has to be kept in mind, that the
TF approach is commonly the first choice when a TAVI is under consideration. Only, if the
condition of the patient’s peripheral vessels does not allow TF TAVI, the TA approach is cho-
sen, leading maybe to an overall sicker patient population. [12]
In the TF group, vascular complications were 6%. In contrast, TA patients had a signifi-
cantly lower rate of vascular complications (2%; p = 0,013). These numbers correspond to
those described in others studies. There, vascular complications occurred in 4–16.4% of
TF-TAVI procedures and 1–4% for TA-TAVI procedures [13–16]. Commonly, in TF access
ilio-femoral vessels are damaged mainly due to the delivery system (6). However, except for
vascular complications, in the TA group more complications were documented.
Most prominent was AKI in the TA group (TA: 18%, TF: 5%; p< 0.001). Whereas these
number correspond to numbers presented in other studies. There, the incidence of AKI is up
to 21.9% in TF patients and up to 44.4% in TA patients. [15,17] Barbash et al. have investigated
the predictors for AKI, specifically for TAVI. [18] The sole independent risk factor identified
by Barbash et al. was the transfusion of erythrocyte concentrates. In our study, the patients
who developed an AKI had a preoperative haemoglobin level that was significantly lower than
the level in patients who did not develop an AKI (11.7 g/dl vs. 12.4 g/dl, p = 0.004). In addition,
the intraoperative and postoperative transfusions of erythrocyte concentrates were associated
with a significantly increased incidence of AKI. Previous research has already shown that the
transfusion of erythrocyte concentrates does not constitute an adequate treatment of perioper-
ative anaemia in all cases. Indeed, the transfusion is associated with increased morbidity and
mortality rates. Early diagnosis and prevention of anaemia is recommended in the context of
patient blood management programs to ensure a more targeted and effective deployment of
transfusions. [19] Overall, the AKI patients in our study were a subgroup featuring a particu-
larly poor preoperative state of health (average EuroScore: 27% vs. 18%, p< 0.001).
In terms of pneumonia and TAVI, we identified only a single study from Covello et al.,
which reported a pneumonia rate of 7–8%. [20] Our incidence of pneumonia was also 7% (TF
6% vs. TA 10%; p = 0.044). According to Lynch et al., the risk factors for hospital-acquired
pneumonia include mechanical ventilation for> 48 h and a long length of stay in the ICU and
Table 3. Time specifications.
all TF (n = 506) TA (n = 347) p
Anaesthesia coverage time (min) 174 ± 49 170 ± 48 180 ± 50 0.007
Induction time (min) 37 ± 12 37 ± 12 39 ± 12 0.131
Procedure time (min) 87 ± 44 86 ± 45 91 ± 43 0.106
Emergence time (min) 7 ± 7 7 ± 7 8 ± 8 0.353
Length of ICU stay (h) 24 (21–38) 24 (21–27) 24 (21–65) <0.001
Length of IMC stay (h) 0 (0–46) 0 (0–0) 18 (0–98) <0.001
Length of hospital stay (d) 9 (7–14) 8 (7–13) 10 (7–15) <0.001
Time to mobilization (h) 19 (11–29) 16 (8–24) 23 (18–42) <0.001
All data are presented as the mean ± standard deviation or as median (IQR).
p < 0.05.
https://doi.org/10.1371/journal.pone.0193558.t003
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the hospital. [21] Our study confirmed these risk factors. According to Hausman et al., COPD
patients are generally exposed to a higher risk of pneumonia for non-cardiosurgical interven-
tions. [22] In our study, the COPD patients also tended to contract pneumonia more fre-
quently (11% vs. 7%, p = 0.172), although the incidence was not statistically significant.
According to the literature, the rate of CVE in TF- and TA-TAVI patients is 1–3.8%. [13–
17] Differences in the incidence of CVEs between TF and TA have not been described. In our
study, 2% of TF patients and 3% of TA patients suffered a CVE, which is comparable to the lit-
erature data.
The incidence of MIs in TAVI patients is up to 1.5%. [13,14,17] In our study, the incidence
was 1%, with no difference between TF (1%) and TA (1%). Although, due to the design of the
study a distinction of the type of MI was not possible, there was a statistically significant associ-
ation between the complications due to intervention and MI. The incidence of MIs in patients
with complications caused by intervention was 3.7%, while only 0.5% of patients without inter-
ventional complications suffered an MI (p = 0.022).
According to the literature, 8.7–28.7% of TF and TA patients need a permanent PM. [13–15]
Differences between TF and TA are not reported, which is supported by our findings (TF: 12%,
TA: 14%; p = 0.46). Studies have cited existing conduction disorders as a risk factor for postop-
erative PM dependency for TAVI and for conventional aortic valve replacement. [23,24] In our
study, this finding was supported by the association between an existing first-degree AV block,
an RBBB and an incomplete LBBB and the implantation of a permanent PM. Typically, patients
with a higher-degree AV block at the preoperative stage had already been fitted with a PM. It is
assumed that the TAVI procedure may cause mechanical damage to the conduction system due
to the anatomical proximity to the aortic valve of a prosthesis that is implanted too deeply. [25]
Also, the valve model by itself has an influence on the PM incidence.
According to the literature, a procedure change from a TAVI to an open surgical interven-
tion occurs in 0–1% of cases. [13,14] In our study procedure changes were necessary in 1% of
cases and mainly resulting from surgical complications.
The mortality rate of TF patients ranges from 4.2% to 8.7%. [13,14,17] The mortality rate of
our TF patients (4%) is comparatively low. The TA patient mortality rate was significantly
higher (9%). In the literature, similarly high mortality rates for TA patients (8–8.8%) can be
found. [15,16] In accordance with our results, Panchal et al. reported in their meta-analysis a
higher mortality in TA. [26] As in our study, they found a higher logistic EuroScore in the TA
group, which might have been linked to higher all-cause mortality. However, other possible
explanations, e.g. a more invasive nature of this approach and its steeper learning curve might
be attributable for increased mortality in TA approach.
A review of the literature for TF access revealed procedure times of 75 ± 40 min to
167.6 ± 5.2 min. [17] The major discrepancies between the studies can probably be attributed
to the lack of a uniform definition of procedure time. In our study, the average procedure time
was 87 ± 44 min (TF: 86 ± 45 min, TA: 91 ± 43 min). According to the literature, the postoper-
ative stay for TF-TAVI patients ranges from 3 ± 4.45 d to 15.5 ± 10.34 d. [13,14,17] For our TF
patients, the average length of hospital stay was 10 d. The TA patients spent a significantly lon-
ger time in the hospital (14 d) than the TF patients. Our average length of hospital stay appears
to be relatively long, but it has to be considered, that the length of stay is strongly dependent
on the local health care system, e.g. the DRG system.
Conclusions
In the present study, we showed that our patients’ outcomes are comparable to those reported
in the available literature and that TA patients have an overall worse physical condition as well
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as a higher perioperative morbidity and mortality. Consequently TA patients need additional
care and should only be operated in appropriately experienced medical centres.
Limitations
During the study period, the proportion of TF-patients in the collective continuously grew to
74.4% in 2015. Furthermore, operative techniques developed over the years and led to a signifi-
cant reduction of complication rates and significant better patient outcome. Therefore, com-
parative interpretation of data between the two access groups must be cautious. Another
limitation is that we did not use the standardized endpoint definitions for transcatheter aortic
valve implantation (VARC-2). [27] urthermore, as we extracted the diagnosis of AKI, MI,
CVE or pneumonia directly from our patient data management system, our retrospective
study design did not allow us to discriminate between the different types. Additionally, only
those data are presented that were documented in the files that were evaluated. Therefore, a
comparison with other studies might be limited.
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